156 Monoclonal Antibody (mAb) CRO and CDMO vendors

What does it take to develop and manufacture a monoclonal antibody (mAb) drug?

A monoclonal antibody program touches more specialist hands than almost any other modality. On the discovery side you need antibody generation (hybridoma, phage or yeast display, or transgenic-animal platforms), then lead engineering: humanization or full human framework selection, affinity maturation, developability screening, and removal of liabilities like aggregation, deamidation, or unwanted glycosylation. That early work decides whether a candidate is even manufacturable, so it is worth getting a partner who screens for developability, not just potency.

The preclinical block covers in vitro pharmacology, binding and functional assays, PK/PD and immunogenicity assessment, and GLP toxicology. The part that separates a specialist CDMO from a generalist is the CMC and manufacturing chain. mAbs are produced in mammalian cells (CHO is the workhorse), so you need stable cell-line development, upstream process development in fed-batch or perfusion, downstream purification built around Protein A capture and polishing chromatography, and a viral clearance strategy. Analytical demands are heavy: glycan profiling, charge variants, aggregation by SEC, host-cell protein and residual DNA, plus a bioassay that reflects mechanism of action.

A generalist contract shop can run a CHO line and fill vials. A specialist mAb CDMO brings proven host cell lines and expression vectors, platform purification processes that shorten timelines, single-use bioreactor trains that scale cleanly, and analytical methods already qualified for antibody-specific attributes. For bispecifics, antibody fragments, or fusion proteins the bar is higher again, and platform experience genuinely shortens the path to GMP material.

How do you choose a CRO or CDMO for monoclonal antibody (mAb) work?

The right partner depends on where you are in the program, but the diligence questions are consistent. Use this as a starting checklist when you shortlist mAb vendors:

• Relevant platform and track record: have they run your exact step (display library, humanization, CHO line development, fed-batch scale-up) for antibodies specifically, and can they name comparable molecules they have taken forward?
• GxP and analytical capability: GLP for tox-enabling studies, GMP for clinical supply, and an analytical package built for antibodies (glycan and charge-variant analysis, Protein A and polishing methods, a qualified potency bioassay).
• Capacity and scale: bioreactor footprint that matches your phase, a credible path from process development to GMP, and single-use versus stainless options that fit your titer and volume.
• Regulatory experience: a documented history supporting IND, IMPD, and BLA filings, plus comfort with viral safety, comparability, and ICH expectations for biologics.
• IP and cell-line rights: clean ownership of the cell line and process, transparent royalties or milestones on any licensed expression system, and a tech-transfer package you actually own if you move sites.